Autopsy report · NCT00346632

An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

“Terminated due to suboptimal dosing schedule”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 10 months before it stopped.
• 37 participants enrolled.
• Results were posted on the registry 8 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Kyowa Kirin, Inc.

Sponsor type

Industry

Conditions

Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia

Interventions

KW-2449

Participants

37

Sites

4

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.